NEM SAP
Natural health product licensed in Canada
- Licence holder
- Nutritional Fundamentals for Health Inc.
- NPN or DIN-HM
- 80045082
- Status
- Active licence
- Licence date
- 27 September 2013
- Revision date
- 20 July 2022
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Boswellia serrata Source : Résine de gomme Potency : 35 % Boswellic acid | 135 mg | Not calculated |
| Boswellia serrata Source : Résine de gomme Potency : 70 % organic acid | Not specified | Not calculated |
| Membrane de coquille d'oeuf de poule partiellement hydrolysée Source : Gallus gallus - Coquille d'oeuf | 500 mg | Not calculated |
Non-medicinal ingredients
Stéarate de magnésium, Dioxyde de silicium, Hypromellose, Eau purifiée
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 18 years | 1 Capsule | 1 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Helps reduce pain associated with osteoarthritis. Helps to reduce stiffness associated with osteoarthritis. Helps to relieve joint pain associated with osteoarthritis. Helps to relieve pain associated with osteoarthritis of the knee. Helps to reduce joint pain associated with osteoarthritis. Helps to reduce stiffness associated with osteoarthritis. Helps to relieve joint pain and stiffness associated with osteoarthritis. Helps to reduce blood C reactive protein levels, a clinical marker of inflammation. Starts to help reduce pain at 5 daysHelps to improve recovery from joint pain and stiffness due to moderate intensity aerobic exercise in post-menopausal women. Helps to minimize discomfort due to moderate intensity aerobic exercise in postmenopausal women. Helps reduce levels of CTX-II, a biomarker/marker of cartilage degradation due to moderate intensity aerobic exercise in post-menopausal women. Helps reduce levels of CTX-II, a biomarker/marker of joint degradation due to moderate intensity aerobic exercise in post-menopausal women. (NEM) Starts to reduce joint pain due to moderate intensity aerobic exercise in as little/as quickly as 1 day and joint stiffness in as little/as quickly as 5 days. (NEM is) Clinically proven to provide relief from joint stiffness due to moderate intensity aerobic exercise (in as little as 5-7 days). (NEM) Helps provide relief from joint pain due to moderate intensity aerobic exercise (as quickly as the first day).
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80045082
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2022. Photograph the packaging to check whether it has changed. Photograph the packaging